Breast Cancer Drugs Market By Therapy, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Breast Cancer Drugs Market," The breast cancer drugs market was valued at $26.4 billion in 2022, and is estimated to reach $59.3 billion by 2032, growing at a CAGR of 8.4% from 2023 to 2032.

Breast cancer is a type of cancer that develops in the breast tissue. It occurs when the cells in the breast grow and divide uncontrollably, forming a tumor. These tumors can be malignant (cancerous) or benign (non-cancerous). It predominantly occurs in women, however, it can also occur in men, although it is relatively rare. It can originate in different parts of the breast, such as the milk ducts, the lobules (which produce milk), or the connective tissue. The most common type of breast cancer occurs in the milk ducts and is known as ductal carcinoma, while cancer originating in the lobules is called lobular carcinoma. Moreover, the treatment for breast cancer involves a combination of different approaches, including chemotherapy, targeted therapy, and hormone therapy. Each treatment modality serves a specific purpose in managing and combating breast cancer, and the selection of treatment depends on various factors, such as the stage & type of breast cancer, the presence of specific receptors, and the patient's overall health & preferences.

The major factors that drive the growth of breast cancer drugs market are rise in prevalence of breast cancer, advancements in diagnostic techniques, and increase in awareness about breast cancer and available treatment options. It is a significant global health concern, impacting millions of women worldwide. The incidence of breast cancer has been steadily rising over the years, making it one of the most prevalent cancers among women. For instance, according to World Health Organization (WHO) 2021, about 2.3 million women were diagnosed with breast cancer globally in 2020, thus rise in prevalence of breast cancer is expected to fuel the growth of market. In addition, early detection and diagnosis are vital in improving the prognosis of breast cancer. Regular breast self-examinations, clinical breast examinations, and mammography screenings can help detect breast cancer in its early stages when treatment is most effective. Thus, advancements in diagnostic techniques for early detection of breast cancer is anticipated to boost the growth of the market.

Furthermore, with rise in incidence of breast cancer cases, there is an upsurge in focus on improving treatment options for breast cancer patients. The objective is to develop drugs that not only enhance survival rates, however, also minimize side effects and improve the quality of life for patients. This drive for better treatment options encourages pharmaceutical companies and researchers to invest in the development of more effective and well-tolerated drugs to treat breast cancer and drive the market growth. Furthermore, growing awareness about breast cancer, its risk factors, and the importance of regular screenings have led to an increase in the number of women undergoing breast cancer screening. In addition, government initiatives, non-profit organizations, and healthcare campaigns have played a crucial role in raising awareness and encourage women to undergo regular mammograms and clinical examinations. Increased screening rates drive early diagnosis and subsequently lead to surge in demand for breast cancer drugs, thus propelling the market growth.

However, factor such as side effects associated with drugs is anticipated to restrain the growth of market. Many breast cancer drugs have associated side effects and toxicities that can affect patients' quality of life. For instance, chemotherapy is known for causing side effects such as hair loss, nausea, fatigue, and immunosuppression, thereby hindering market growth. Moreover, rise in demand for novel therapeutics for treating breast cancer, increase in R&D activities for development of new and more effective drugs, and rise in regulatory approvals for anticancer drugs are expected to offer lucrative opportunities to key players of breast cancer drugs market.

The breast cancer drugs market is segmented on the basis of therapy, age group, distribution channel, and region. On the basis of therapy, the market is categorized into chemotherapy, hormonal therapy, targeted therapy, and immunotherapy. On the basis of age group, the market is bifurcated into below 55 years and above 55 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major Key players that operate in the global breast cancer drugs market are Gilead Sciences, Inc., Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd., and F. Hoffmann-La Roche Ltd. The key players have adopted strategies such as acquisition, funding, product launch, and product approval to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the breast cancer drugs market analysis from 2022 to 2032 to identify the prevailing breast cancer drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the breast cancer drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global breast cancer drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy

Chemotherapy
Hormonal therapy
Targeted therapy
Immunotherapy

By Age group

Below 55 years
Above 55 years

By Distribution channel

Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Merck & Co., Inc.
Zydus Lifesciences Limited
Gilead Sciences, Inc.
Novartis AG
Eli Lilly and Company
AstraZeneca plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.

Product Code: A11123

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of breast cancer
  - 3.4.1.2. Advancements in diagnostic technologies
  - 3.4.1.3. High investments in research and development

3.4.2. Restraints
- 3.4.2.1. Adverse effects associated with the use cancer drugs

3.4.3. Opportunities
- 3.4.3.1. High growth potential in untapped emerging economies

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BREAST CANCER DRUGS MARKET, BY THERAPY

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Chemotherapy
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Hormonal therapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Targeted therapy
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Immunotherapy
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: BREAST CANCER DRUGS MARKET, BY AGE GROUP

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Below 55 years
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Above 55 years
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: BREAST CANCER DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Therapy
- 7.2.3. Market size and forecast, by Age group
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Therapy
  - 7.2.5.1.3. Market size and forecast, by Age group
  - 7.2.5.1.4. Market size and forecast, by Distribution channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Therapy
  - 7.2.5.2.3. Market size and forecast, by Age group
  - 7.2.5.2.4. Market size and forecast, by Distribution channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Therapy
  - 7.2.5.3.3. Market size and forecast, by Age group
  - 7.2.5.3.4. Market size and forecast, by Distribution channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Therapy
- 7.3.3. Market size and forecast, by Age group
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Therapy
  - 7.3.5.1.3. Market size and forecast, by Age group
  - 7.3.5.1.4. Market size and forecast, by Distribution channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Therapy
  - 7.3.5.2.3. Market size and forecast, by Age group
  - 7.3.5.2.4. Market size and forecast, by Distribution channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Therapy
  - 7.3.5.3.3. Market size and forecast, by Age group
  - 7.3.5.3.4. Market size and forecast, by Distribution channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Therapy
  - 7.3.5.4.3. Market size and forecast, by Age group
  - 7.3.5.4.4. Market size and forecast, by Distribution channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Therapy
  - 7.3.5.5.3. Market size and forecast, by Age group
  - 7.3.5.5.4. Market size and forecast, by Distribution channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Therapy
  - 7.3.5.6.3. Market size and forecast, by Age group
  - 7.3.5.6.4. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Therapy
- 7.4.3. Market size and forecast, by Age group
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Therapy
  - 7.4.5.1.3. Market size and forecast, by Age group
  - 7.4.5.1.4. Market size and forecast, by Distribution channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Therapy
  - 7.4.5.2.3. Market size and forecast, by Age group
  - 7.4.5.2.4. Market size and forecast, by Distribution channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Therapy
  - 7.4.5.3.3. Market size and forecast, by Age group
  - 7.4.5.3.4. Market size and forecast, by Distribution channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Therapy
  - 7.4.5.4.3. Market size and forecast, by Age group
  - 7.4.5.4.4. Market size and forecast, by Distribution channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Therapy
  - 7.4.5.5.3. Market size and forecast, by Age group
  - 7.4.5.5.4. Market size and forecast, by Distribution channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Therapy
  - 7.4.5.6.3. Market size and forecast, by Age group
  - 7.4.5.6.4. Market size and forecast, by Distribution channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Therapy
- 7.5.3. Market size and forecast, by Age group
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Therapy
  - 7.5.5.1.3. Market size and forecast, by Age group
  - 7.5.5.1.4. Market size and forecast, by Distribution channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Therapy
  - 7.5.5.2.3. Market size and forecast, by Age group
  - 7.5.5.2.4. Market size and forecast, by Distribution channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Therapy
  - 7.5.5.3.3. Market size and forecast, by Age group
  - 7.5.5.3.4. Market size and forecast, by Distribution channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Therapy
  - 7.5.5.4.3. Market size and forecast, by Age group
  - 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Novartis AG
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Pfizer Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. AstraZeneca plc
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Eli Lilly and Company
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Merck & Co., Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Bristol-Myers Squibb Company
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Zydus Lifesciences Limited
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. F. Hoffmann-La Roche Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Gilead Sciences, Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments